Management of Acute Coronary Syndromes

Lieferzeit: Lieferbar innerhalb 14 Tagen

213,99 

Contemporary Cardiology

ISBN: 1588291308
ISBN 13: 9781588291301
Herausgeber: Christopher P Cannon
Verlag: Humana Press
Umfang: xv, 783 S.
Erscheinungsdatum: 04.11.2002
Auflage: 1/2002
Produktform: Gebunden/Hardback
Einband: Gebunden

In this second edition of his highly acclaimed book, Christopher P. Cannon, MD, and a team of preeminent clinical investigators have thoroughly revised and expanded every chapter to reflect the recent explosion of clinical trials on the management of acute coronary syndromes (ACS). These world-renowned experts review: the newer tests, such as C reactive protein; a multimarker approach to diagnosis and risk stratification; new antiplatelet agents; and combinations of thrombolytic-anti- thrombotic regimens. They also discuss the latest developments in interventional cardiology (early invasive approach in higher risk ACS patients and the promise of drug-coated stents), and analyze cost-effectiveness in clinical trials to choose appropriate therapies. Current trial data are included, along with practical recommendations on how these data may be applied in daily practice. Comprehensive and authoritative, Management of Acute Coronary Syndromes, Second Edition, succinctly presents cardiologists, internists, primary care and emergency physicians, fellows, and residents with an up-to-the-minute review of the many recent advances that have transformed our understanding of the pathophysiology, diagnosis, and management of patients with acute coronary syndromes.

Artikelnummer: 5024880 Kategorie:

Beschreibung

In this second edition of his highly acclaimed book, Christopher P. Cannon, MD, and a team of preeminent clinical investigators have thoroughly revised and expanded every chapter to reflect the recent explosion of clinical trials on the management of acute coronary syndromes (ACS). This includes: the newer tests, such as C reactive protein; a multimarker approach to diagnosis and risk stratification; new antiplatelet agents; and combinations of thrombolytic-antithrombotic regimens. Also discussed are the latest developments in interventional cardiology, the use of cost-effectiveness in clinical trials to choose appropriate therapies, and the employment of critical pathways analysis to improve compliance with evidence-based medicine and guideline recommendations.

Herstellerkennzeichnung:


Humana Press in Springer Science + Business Media
Heidelberger Platz 3
14197 Berlin
DE

E-Mail: juergen.hartmann@springer.com

Das könnte Ihnen auch gefallen …